Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pozelimab - Regeneron Pharmaceuticals

Next Previous
Drug Profile

Pozelimab - Regeneron Pharmaceuticals

Alternative Names: Pozelimab-bbfg; REGN 3918; Veopoz

Latest Information Update: 11 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Regeneron Pharmaceuticals
  • Class Anti-inflammatories; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Protein-losing enteropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Protein-losing enteropathy
  • Phase III Dry macular degeneration; Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 08 Dec 2024 Efficacy and adverse events data from a phase III ACCESS-1 trial in Paroxysmal nocturnal hemoglobinuria released by Regeneron Pharmaceuticals
  • 08 Dec 2024 Efficacy and adverse events data from a phase III OLE (ACCESS-EXTENSION) trial in Paroxysmal nocturnal hemoglobinuria released by Regeneron Pharmaceuticals
  • 31 Oct 2024 Phase-III clinical trials in Dry macular degeneration (Combination therapy) (SC) prior to October 2024 (NCT06541704)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top